

John C Mcvey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714834/publications.pdf>

Version: 2024-02-01

17
papers

346
citations

932766

10
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

570
citing authors

#	ARTICLE	IF	CITATIONS
1	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 1145-1154.	1.8	76
2	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 748-760.	1.8	57
3	Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
4	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , 2020, 71, 569-582.	3.6	30
5	Elevated Risk of Split-Liver grafts in adult liver Transplantation: Statistical Artifact or Nature of the Beast?. <i>Liver Transplantation</i> , 2019, 25, 741-751.	1.3	28
6	Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. <i>Hepatology</i> , 2018, 68, 1448-1458.	3.6	18
7	Improved Survival Following Living Donor Liver Transplantation for Pediatric Acute Liver Failure: Analysis of 20 Years of US National Registry Data. <i>Liver Transplantation</i> , 2019, 25, 1241-1250.	1.3	17
8	Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1166-1178.	2.3	15
9	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. <i>IScience</i> , 2022, 25, 103847.	1.9	12
10	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. <i>IScience</i> , 2021, 24, 101990.	1.9	11
11	Conditional probability of graft survival in liver transplantation using donation after circulatory death grafts - a retrospective study. <i>Transplant International</i> , 2021, 34, 1433-1443.	0.8	8
12	KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. <i>Hpb</i> , 2019, 21, 1527-1534.	0.1	7
13	The impact of resection margin on overall survival for patients with colon cancer liver metastasis varied according to the primary cancer location. <i>Hpb</i> , 2019, 21, 702-710.	0.1	7
14	Prognostication of inflammatory cells in liver transplantation: Is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology?. <i>Clinical Transplantation</i> , 2019, 33, e13743.	0.8	6
15	Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. <i>Clinical Transplantation</i> , 2019, 33, e13723.	0.8	3
16	Should We Be Utilizing More Liver Grafts From Pediatric Donation After Circulatory Death Donors? A National Analysis of the SRTR from 2002 to 2017. <i>Transplantation</i> , 2021, 105, 1998-2006.	0.5	3
17	Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. <i>Hepatic Oncology</i> , 2020, 7, HEP26.	4.2	2